Lung cancer Committee meeting

Date: 18/06/2018 & 19/06/18
Location: NICE offices London
Minutes: Final

Committee members present:

<table>
<thead>
<tr>
<th>Name</th>
<th>Present for</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gary McVeigh (GM) (Chair)</td>
<td>all</td>
</tr>
<tr>
<td>Shahzeena Aslam (SA)</td>
<td>all</td>
</tr>
<tr>
<td>Elaine Borg (EB)</td>
<td>all</td>
</tr>
<tr>
<td>Lynn Campbell (LC)</td>
<td>all</td>
</tr>
<tr>
<td>Sujal Desai (SD)</td>
<td>all</td>
</tr>
<tr>
<td>Jesme Fox (JF)</td>
<td>all</td>
</tr>
<tr>
<td>Tom Haswell (TH)</td>
<td>all</td>
</tr>
<tr>
<td>Andrea McIver (AM)</td>
<td>all</td>
</tr>
<tr>
<td>Sue Maughn (SM)</td>
<td>all</td>
</tr>
<tr>
<td>Neal Navani (NN)</td>
<td>all</td>
</tr>
<tr>
<td>Steve Connor (SC)</td>
<td>Day 2 from item 6</td>
</tr>
<tr>
<td>Rhiannon Walters-Davies (RW)</td>
<td>Present for day 1</td>
</tr>
<tr>
<td>Douglas West (DW)</td>
<td>Present from item partway through item 2, day 1</td>
</tr>
<tr>
<td></td>
<td>Present for all day 2</td>
</tr>
<tr>
<td>Nigel Westwood</td>
<td>Present from item partway through item 2, day 1</td>
</tr>
<tr>
<td></td>
<td>Present for all day 2</td>
</tr>
<tr>
<td>Clifford Wyn Jones (CW)</td>
<td>Present from item partway through item 2, day 1</td>
</tr>
<tr>
<td></td>
<td>Present for all day 2</td>
</tr>
</tbody>
</table>

In attendance:

<table>
<thead>
<tr>
<th>Name</th>
<th>Present for all day 1</th>
<th>Present from partway</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sohaib Ashraf (SAS)</td>
<td>NICE – Technical Analyst Health Economics</td>
<td></td>
</tr>
</tbody>
</table>
4.0.03 DOC Cmte minutes

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Attendance</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Hall (JH)</td>
<td>NICE – Editor</td>
<td>Present for all</td>
</tr>
<tr>
<td>Ross Maconachie (RM)</td>
<td>NICE – Technical Advisor</td>
<td>Present for all day 1, Present from partway through item 2, day 2</td>
</tr>
<tr>
<td>Toby Mercer (TM)</td>
<td>NICE – Technical Analyst</td>
<td>Present for all</td>
</tr>
<tr>
<td>Caroline Mulvihill (CM)</td>
<td>NICE – Technical Advisor</td>
<td>Present for all</td>
</tr>
<tr>
<td>Vonda Murray (VM)</td>
<td>NICE – Project Manager</td>
<td>Present for all</td>
</tr>
</tbody>
</table>

**Observers:**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rui Martins</td>
<td>NICE - Technical Analyst Health Economics – present for day 1, until item 4</td>
</tr>
<tr>
<td>Shreya Shukla</td>
<td>NICE - Technical analyst – present for day 1, until item 4</td>
</tr>
<tr>
<td>Jeffrey Tabiri-Essuman</td>
<td>NICE - Technical analyst – present for day 1, until item 4</td>
</tr>
</tbody>
</table>

**Apologies:**

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steve Connor</td>
<td>Committee member – day 1</td>
</tr>
<tr>
<td>Rupert Franklin</td>
<td>NICE – Commissioning Manager - day 1 &amp; 2</td>
</tr>
<tr>
<td>Sue Spiers</td>
<td>NICE – Associate Director Guideline Updates Team day 1 &amp; 2</td>
</tr>
<tr>
<td>Rhiannon Walters-Davies</td>
<td>Committee member – day 2</td>
</tr>
</tbody>
</table>

Day 1 – Monday 18th June 2018

**Item 1**

- Welcome
- Objectives
- Declarations of interest
- Minutes of the last meeting

**Item 1**

The Chair welcomed the Committee members, and attendees to day 1, of the 7th committee meeting on lung cancer.

The objectives of the meeting, were outlined by the Chair, for day 1 of the meeting. The minutes were reviewed from Gcomm 6; Wednesday 16th May 2018. The minutes were agreed to be an accurate record.

The DOI register was made available to the Chair, and committee. The Chair reviewed the DOI register, a number of new declarations were made, and these are
noted below. The DOI’s were considered by the Chair. It was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

<table>
<thead>
<tr>
<th>Attendee</th>
<th>Declaration</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shahzeena Aslam</td>
<td>Attendance at Oncology Forum meeting June 2018, Liverpool. Covers general oncology updates, with one session dedicated to lung cancer management. Nothing covered in the meeting, is covered by the guideline update. (Flights and accommodation. No registration fee). Organised by UK Oncologists and sponsored by a number of pharmacological companies, predominantly Novartis, Health care at Home.</td>
<td>Direct financial. Declare and participate. Not specific to any topic covered in the scope of the guideline</td>
</tr>
<tr>
<td>Shahzeena Aslam</td>
<td>Paid work for IQVIA clinical research organisation. Involves analysis of anonymous data that has been collected from patients including lung cancer patients with an emphasis on recurrence, toxicity and death. Data collected will be “real world” data from patients not enrolled in clinical trials but undergoing pharmacological treatment with licensed drugs.</td>
<td>Direct financial. Declare and participate The work is provision of generic real world data with no direct link to the scope of the guideline</td>
</tr>
<tr>
<td>Lynn Campbell</td>
<td>Attendance at Oncology Forum meeting June 2018, Liverpool. Covers general oncology updates, with one session dedicated to lung cancer management. Nothing covered in the meeting, is covered by the guideline update. (Flights and accommodation. No registration fee). Organised by UK Oncologists and sponsored by a number of pharmacological companies, predominantly Novartis, Health care at Home.</td>
<td>Direct financial (non-specific) (travel and subsistence only) Declare and participate Not specific to any topic covered in the scope of the guideline</td>
</tr>
<tr>
<td>Sujal Desai</td>
<td>Run an educational course for Boehringer Ingelheim, on interstitial lung diseases. Honorarium and travel costs will be paid</td>
<td>Direct financial (non-specific). Declare and participate Not specific to any topic covered in the scope of the guideline</td>
</tr>
<tr>
<td>Jesme Fox</td>
<td>31st May, attended a Global Oncology Advocacy Leaders Meeting in Chicago. Travel and accommodation expenses paid by Bristol-Myers Squibb. The topics</td>
<td>Direct financial (travel and subsistence), (non-specific)</td>
</tr>
</tbody>
</table>
4.0.03 DOC Cmte minutes

discussed general cancer issues, not relevant to lung cancer guideline. | Declare and participate Not specific to any topic covered in the scope of the guideline
---|---
Rhiannon Walter-Davies | Attend an advisory board, for Astra Zeneca, 5th July 2018, on Durvalumab. Accommodation, travel and expenses paid. Honorarium paid to education fund. The topics discussed, were not relevant to lung cancer guideline. | In direct financial (non-specific) Declare and participate Not specific to any topic covered in the scope of the guideline
Rhiannon Walter-Davies | Attend an internal meeting (educational) for Boehringer, 26th June 2018, on Afatanib. Honorarium paid to education fund. Accommodation, travel and expenses paid. | In direct financial Declare and participate
Rhiannon Walter-Davies | Attendance at Oncology Forum meeting June 2018, Liverpool. Covers general oncology updates, with one session dedicated to lung cancer management. Nothing covered in the meeting, is covered by the guideline update. (Flights and accommodation. No registration fee). Organised by UK Oncologists and sponsored by a number of pharmacological companies, predominantly Novartis, Health care at Home. | Direct financial (travel and subsistence) Declare and participate Not specific to any topic covered in the scope of the guideline

**Item 2**
Lay members slot

**Item 2**
Lay members given the opportunity to ask questions of NICE staff relating to the review questions.

**Item 3**
Algorithm feedback from targeted consultation

**Item 3**
CM presented the comments received from the targeted consultation exercise. The committee discussed the comments, and agreed changes to the algorithm as required.

**Item 4**
3.1 What is the clinical and cost effectiveness of chemotherapy, radiotherapy or surgery (alone or in combination) for the treatment for N2 stage NSCLC?
- Presentation of network meta-analyses
- Discuss economic model
4.0.03 DOC Cmte minutes

**Item 4**
RM presented the network meta-analyses, on clinical and cost effectiveness of chemotherapy, radiotherapy or surgery (alone or in combination) for the treatment for N2 stage non-small cell lung cancer. The committee discussed the evidence presented. RM also presented the finalised economic model structure and the underpinning data. The committee discussed these.

**Item 5**
3.1 What is the clinical and cost effectiveness of chemotherapy, radiotherapy or surgery (alone or in combination) for the treatment for N2 stage NSCLC?
- Discuss health economic model results
- Agree recommendations

**Item 5**
RM presented the results of the health economic model. The committee discussed the evidence presented, and reviewed and updated recommendations accordingly.

**Item 6**
3.2 What is the clinical and cost effectiveness of different radiotherapy regimens with curative intent for NSCLC (stage T1a–2b N0 M0)?
- Evidence review
- Health economics
- Agree recommendations

**Item 6**
TM presented the evidence found on, what is the clinical and cost effectiveness of different radiotherapy regimens with curative intent for NSCLC (stage T1a–2b N0 M0).

**Item 7**
3.2 What is the clinical and cost effectiveness of different radiotherapy regimens with curative intent for NSCLC (stage T1a–2b N0 M0)?
- Agree recommendations

**Item 7**
TM presented additional evidence for this review question. The committee discussed the evidence presented, and reviewed and updated recommendations accordingly.

**Item 8**
4.1 What is the clinical and cost effectiveness of cranial irradiation for brain metastases in people with NSCLC?
- Brain tumours (primary) and brain metastases in adults recommendations discussion

**Item 8**
Brought forward from day 2, item 5. CM presented the recommendation made by the
4.0.03 DOC Cmte minutes

Brain Tumour and Brain Metastases Guideline Committee. The committee discussed this and agreed recommendations.

**Item 9**
AOB

**Item 9**
No other business to discuss

**Item 10**
Summary and next steps

**Item 10**
The Chair thanked the committee for their contribution, and the committee agreed a revised start time for day 2 of GComm7.

---

**Day 2 – Tuesday 19th June 2018**

**Item 1**
- Welcome
- Objectives
- Declarations of interest

**Item 1**
The Chair welcomed the Committee members, and attendees to day 2, of the 7th committee meeting on lung cancer.

The DOI register was made available to the Chair, and committee. The DOI’s were considered by the Chair. It was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

Apologies were noted, as recorded above. The objectives of the meeting, were outlined by the Chair, for day 2 of the meeting.

**Item 2**
Lay members slot

**Item 2**
Lay members given the opportunity to ask questions of NICE staff relating to the review questions.

**Item 3**
- Recommendation refresh
  - Impact review of recommendations
  - Staging
CM went through the recommendations, the committee reviewed the recommendations, considering how they impacted upon each other and whether any terminology was outdated. Recommendations were updated accordingly.

**Item 4**
- Edited recommendations

**Item 4**
CM went through the recommendations that have been made to date, providing feedback from the Editor on the recommendations. The committee reviewed and updated recommendations accordingly.

**Item 5**

4.1 What is the clinical and cost effectiveness of cranial irradiation for brain metastases in people with NSCLC?
- Brain tumours (primary) and brain metastases in adults recommendations discussion

**Item 5**
Brought forward to day 1, item 8

**Item 6**

1.3 What is the clinical and cost-effectiveness of routine imaging of the head in the management of people with lung cancer before radical therapy with curative intent?
- Discuss health economics

**Item 6**
The Chair welcomed SC, Neuroradiologist to the committee. SC introduced himself to the committee. The Chair reviewed SC’s, DOI’s and these are noted below.

<table>
<thead>
<tr>
<th>Attendee</th>
<th>Declaration</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steve Connor</td>
<td>Receives payment for work in private hospitals. Paid directly. 95% of private practice fees from HCA insurance. 1/6 of the working week is spent in private practice. Private practice is for general neuroradiology imaging and none in relation to lung cancer.</td>
<td>Direct Financial (non-specific) No action other than the process of open declaration</td>
</tr>
<tr>
<td>Steve Connor</td>
<td>Research collaborations with head and neck oncology groups, in regards to head and neck cancer treatment. Not related to the scope of this guideline update.</td>
<td>Non-financial (non-specific) No action other than the process of open declaration</td>
</tr>
</tbody>
</table>

RM presented the results of the economic model on routine imaging of the head in
the management of people with non-small cell lung cancer before radical therapy with curative intent.

**Item 7**

1.3 What is the clinical and cost-effectiveness of routine imaging of the head in the management of people with lung cancer before radical therapy with curative intent?
   - Discuss health economics
   - Agree recommendations

**Item 7**
The committee discussed the results of the health economic model and then reviewed and updated the recommendations accordingly.

**Item 8**
- AOB

**Item 8**
No other business

**Item 9**
- Summary and next steps

**Item 9**
The Chair thanked the committee for their hard work over the 2 day meeting.

**Date of next meeting:** Thursday 26th July 2018

**Location of next meeting:** NICE Offices – Manchester